Advertisement
Advertisement

CRVO

CRVO logo

CervoMed Inc. Common Stock

4.05
USD
Sponsored
+0.13
+3.32%
Mar 25, 15:58 UTC -4
Closed
exchange

After-Market

4.05

0.00
0.00%

CRVO Earnings Reports

Positive Surprise Ratio

CRVO beat 14 of 30 last estimates.

47%

Next Report

Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$122.40K
/
-$0.78
Implied change from Q4 25 (Revenue/ EPS)
+1260.00%
/
-11.36%
Implied change from Q1 25 (Revenue/ EPS)
-93.62%
/
+39.29%

CervoMed Inc. Common Stock earnings per share and revenue

On Mar 13, 2026, CRVO reported earnings of -0.88 USD per share (EPS) for Q4 25, missing the estimate of -0.73 USD, resulting in a -20.30% surprise. Revenue reached 9.00 thousand, compared to an expected 859.72 thousand, with a -98.95% difference. The market reacted with a +1.41% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.78 USD, with revenue projected to reach 122.40 thousand USD, implying an decrease of -11.36% EPS, and increase of 1260.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
logo
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
logo
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
logo
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
logo
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
logo
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
logo
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
For Q4 2025, CervoMed Inc. Common Stock reported EPS of -$0.88, missing estimates by -20.3%, and revenue of $9.00K, -98.95% below expectations.
The stock price moved up 1.41%, changed from $4.25 before the earnings release to $4.31 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 7 analysts, CervoMed Inc. Common Stock is expected to report EPS of -$0.78 and revenue of $122.40K for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement